Colchicine a New Tool for Stroke, CVD Event Recurrence? : co

The CONVINCE trial of the anti-inflammatory drug colchicine missed its primary endpoint, but secondary analyses suggested benefit.

Related Keywords

Dublin , Ireland , Switzerland , Canada , Mira Katan , Peter Kelly , European Stroke Organization Conference , University College Dublin School Of Medicine , University Hospital Of Basel , University College Dublin School , Novel Target , University Hospital ,